AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major ...
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...
AstraZeneca is forecast to report core earnings per share--its preferred metric, which strips out exceptional and other one-off items--of $2.54, according ...
"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...
AstraZeneca plc (NASDAQ:AZN) has been granted approval by the U.S. Food and Drug Administration for a new self-injection ...
AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...
AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...
AstraZeneca plc (LSE:AZN) has received approval from the U.S. Food and Drug Administration for a new self-administered ...
The initiative aims to make the US more competitive for drug research as companies increasingly choose to launch trials in ...
AstraZeneca said on Monday its experimental treatment tozorakimab showed a "meaningful reduction" in moderate-to-severe ...
Clinical Trials Arena on MSN
AstraZeneca’s COPD drug gains third Phase III win
Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results